The study aims to investigate immunomodulatory effects of eltrombopag combined with
dexamethasone in young adult patients with newly diagnosed primary Immune thrombocytopenia
(ITP).
Phase:
Phase 2
Details
Lead Sponsor:
University Children's Hospital Basel University Hospital, Basel, Switzerland
Collaborators:
Novartis Pharmaceuticals Stiftung zur Förderung medizinischer und biologischer Forschung University of Erlangen-Nürnberg, Department of Biology